Literature DB >> 32008217

Cytoplasmic ERα and NFκB Promote Cell Survival in Mouse Mammary Cancer Cell Lines.

Emily Smart1, Luis H Alejo1, Jonna Frasor2.   

Abstract

There is a desperate need in the field for mouse mammary tumors and cell lines that faithfully mimic estrogen receptor (ER) expression and activity found in human breast cancers. We found that several mouse mammary cancer cell lines express ER but fail to demonstrate classical estrogen-driven proliferation or transcriptional activity. We investigated whether these cell lines may be used to model tamoxifen resistance by using small molecule inhibitors to signaling pathways known to contribute to resistance. We found that the combination of NFκB inhibition and ER antagonists significantly reduced cell proliferation in vitro, as well as growth of syngeneic tumors. Surprisingly, we found that ER was localized to the cytoplasm, regardless of any type of treatment. Based on this, we probed extra-nuclear functions of ER and found that co-inhibition of ER and NFκB led to an increase in oxidative stress and apoptosis. Together, these findings suggest that cytoplasmic ER and NFκB may play redundant roles in protecting mammary cancer cells from oxidative stress and cell death. Although this study has not identified a mouse model with classical ER activity, cytoplasmic ER has been described in a small subset of human breast tumors, suggesting that these findings may be relevant for some breast cancer patients.

Entities:  

Keywords:  Estrogen receptor; Mammary cancer; Mouse; NFκB; Tamoxifen

Mesh:

Substances:

Year:  2020        PMID: 32008217      PMCID: PMC7386283          DOI: 10.1007/s12672-020-00378-2

Source DB:  PubMed          Journal:  Horm Cancer        ISSN: 1868-8497            Impact factor:   3.869


  75 in total

Review 1.  Crosstalk of reactive oxygen species and NF-κB signaling.

Authors:  Michael J Morgan; Zheng-gang Liu
Journal:  Cell Res       Date:  2010-12-28       Impact factor: 25.617

2.  Estrogen receptor positivity in mammary tumors of Wnt-1 transgenic mice is influenced by collaborating oncogenic mutations.

Authors:  Xiaomei Zhang; Katrina Podsypanina; Shixia Huang; Syed K Mohsin; Gary C Chamness; Sarah Hatsell; Pam Cowin; Rachel Schiff; Yi Li
Journal:  Oncogene       Date:  2005-06-16       Impact factor: 9.867

3.  Estrogen receptor-positive mammary tumorigenesis in TGFalpha transgenic mice progresses with progesterone receptor loss.

Authors:  T A Rose-Hellekant; M D Schroeder; J L Brockman; O Zhdankin; R Bolstad; K S Chen; M N Gould; L A Schuler; E P Sandgren
Journal:  Oncogene       Date:  2007-03-05       Impact factor: 9.867

4.  Non-nuclear estrogen receptor alpha activation in endothelium reduces cardiac ischemia-reperfusion injury in mice.

Authors:  Sara Menazza; Junhui Sun; Swathi Appachi; Ken L Chambliss; Sung Hoon Kim; Angel Aponte; Sohaib Khan; John A Katzenellenbogen; Benita S Katzenellenbogen; Philip W Shaul; Elizabeth Murphy
Journal:  J Mol Cell Cardiol       Date:  2017-04-27       Impact factor: 5.000

5.  Activation of nuclear factor-kappaB (NFkappaB) identifies a high-risk subset of hormone-dependent breast cancers.

Authors:  Yamei Zhou; Serenella Eppenberger-Castori; Corina Marx; Christina Yau; Gary K Scott; Urs Eppenberger; Christopher C Benz
Journal:  Int J Biochem Cell Biol       Date:  2005-05       Impact factor: 5.085

6.  Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases.

Authors:  Elaine Y Lin; Joan G Jones; Ping Li; Liyin Zhu; Kathleen D Whitney; William J Muller; Jeffrey W Pollard
Journal:  Am J Pathol       Date:  2003-11       Impact factor: 4.307

7.  Amphiregulin is an essential mediator of estrogen receptor alpha function in mammary gland development.

Authors:  Laura Ciarloni; Sonia Mallepell; Cathrin Brisken
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-16       Impact factor: 11.205

Review 8.  Patient-derived xenograft (PDX) models in basic and translational breast cancer research.

Authors:  Lacey E Dobrolecki; Susie D Airhart; Denis G Alferez; Samuel Aparicio; Fariba Behbod; Mohamed Bentires-Alj; Cathrin Brisken; Carol J Bult; Shirong Cai; Robert B Clarke; Heidi Dowst; Matthew J Ellis; Eva Gonzalez-Suarez; Richard D Iggo; Peter Kabos; Shunqiang Li; Geoffrey J Lindeman; Elisabetta Marangoni; Aaron McCoy; Funda Meric-Bernstam; Helen Piwnica-Worms; Marie-France Poupon; Jorge Reis-Filho; Carol A Sartorius; Valentina Scabia; George Sflomos; Yizheng Tu; François Vaillant; Jane E Visvader; Alana Welm; Max S Wicha; Michael T Lewis
Journal:  Cancer Metastasis Rev       Date:  2016-12       Impact factor: 9.264

Review 9.  The interaction between ER and NFκB in resistance to endocrine therapy.

Authors:  Leen Sas; Filip Lardon; Peter B Vermeulen; Jan Hauspy; Peter Van Dam; Patrick Pauwels; Luc Y Dirix; Steven J Van Laere
Journal:  Breast Cancer Res       Date:  2012-08-31       Impact factor: 6.466

10.  Immunocompetent mouse allograft models for development of therapies to target breast cancer metastasis.

Authors:  Yuan Yang; Howard H Yang; Ying Hu; Peter H Watson; Huaitian Liu; Thomas R Geiger; Miriam R Anver; Diana C Haines; Philip Martin; Jeffrey E Green; Maxwell P Lee; Kent W Hunter; Lalage M Wakefield
Journal:  Oncotarget       Date:  2017-05-09
View more
  5 in total

1.  TAp63 regulates bone remodeling by modulating the expression of TNFRSF11B/Osteoprotegerin.

Authors:  Anna Maria Lena; Erica Foffi; Massimiliano Agostini; Mara Mancini; Margherita Annicchiarico-Petruzzelli; Daniel Aberdam; Tania Velletri; Yufang Shi; Gerry Melino; Ying Wang; Eleonora Candi
Journal:  Cell Cycle       Date:  2021-11-11       Impact factor: 4.534

2.  Estrogen Receptor-Regulated Gene Signatures in Invasive Breast Cancer Cells and Aggressive Breast Tumors.

Authors:  Emily Smart; Svetlana E Semina; Luis H Alejo; Nidhi S Kansara; Jonna Frasor
Journal:  Cancers (Basel)       Date:  2022-06-09       Impact factor: 6.575

3.  Endocrine Therapy-Resistant Breast Cancer Cells Are More Sensitive to Ceramide Kinase Inhibition and Elevated Ceramide Levels Than Therapy-Sensitive Breast Cancer Cells.

Authors:  Purab Pal; Alec Millner; Svetlana E Semina; Rosemary J Huggins; Logan Running; Diana S Aga; Debra A Tonetti; Rachel Schiff; Geoffrey L Greene; G Ekin Atilla-Gokcumen; Jonna Frasor
Journal:  Cancers (Basel)       Date:  2022-05-12       Impact factor: 6.575

Review 4.  Long non-coding RNAs affecting cell metabolism in cancer.

Authors:  Massimiliano Agostini; Mara Mancini; Eleonora Candi
Journal:  Biol Direct       Date:  2022-10-01       Impact factor: 7.173

Review 5.  Update on the Role of NFκB in Promoting Aggressive Phenotypes of Estrogen Receptor-Positive Breast Cancer.

Authors:  Emily Smart; Svetlana E Semina; Jonna Frasor
Journal:  Endocrinology       Date:  2020-10-01       Impact factor: 4.736

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.